Last updated on August 2017

Study Of Diabetic Nephropathy With Atrasentan

Brief description of study

This study is being conducted to evaluate the effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy.

Detailed Study Description

The study objective is to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine or the onset of end stage renal disease (ESRD) in subjects with type 2 diabetes and nephropathy who are treated with the maximum tolerated labeled daily dose (MTLDD) of a Renin Angiotensin System (RAS) inhibitor. In addition, the study will assess the effects of atrasentan compared with placebo on cardiovascular morbidity and mortality, urine albumin excretion, changes in estimated glomerular filtration rate (eGFR), as well as on the impact on quality of life in subjects with type 2 diabetes and nephropathy.

Clinical Study Identifier: NCT01858532

Contact Investigators or Research Sites near you

Start Over

AbbVie_Call Center

Boice-Willis Clinic, P.A. /ID# 104903
Rocky Mount, NC United States
  Connect »